Volume | 583,706 |
|
|||||
News | - | ||||||
Day High | 22.20 | Low High |
|||||
Day Low | 21.048 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cassava Sciences Inc | SAVA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
21.50 | 21.048 | 22.20 | 21.71 | 21.30 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,451 | 583,706 | $ 21.71 | $ 12,673,964 | - | 12.3202 - 45.4287 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:17 | 2 | $ 21.72 | USD |
Cassava Sciences (SAVA) Options Flow Summary
Cassava Sciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
915.6M | 42.17M | - | 0 | -76.25M | -1.81 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cassava Sciences News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAVA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 20.66 | 22.4069 | 20.50 | 21.24 | 625,603 | 1.14 | 5.52% |
1 Month | 22.66 | 23.7938 | 19.20 | 21.41 | 757,211 | -0.86 | -3.8% |
3 Months | 19.40 | 25.46 | 12.3202 | 18.44 | 1,245,784 | 2.40 | 12.37% |
6 Months | 22.81 | 27.21 | 12.3202 | 19.66 | 1,056,895 | -1.01 | -4.43% |
1 Year | 33.74 | 45.4287 | 12.3202 | 24.28 | 1,056,152 | -11.94 | -35.39% |
3 Years | 7.76 | 146.16 | 6.70 | 50.44 | 2,912,281 | 14.04 | 180.93% |
5 Years | 1.21 | 146.16 | 1.00 | 34.62 | 2,894,860 | 20.59 | 1,701.65% |
Cassava Sciences Description
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. |